201 related articles for article (PubMed ID: 23593207)
1. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.
Kushner LE; Wendelboe AM; Lazzeroni LC; Chary A; Winters MA; Osinusi A; Kottilil S; Polis MA; Holodniy M
PLoS One; 2013; 8(4):e60387. PubMed ID: 23593207
[TBL] [Abstract][Full Text] [Related]
2. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Nilsson J; Weiland O
Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
Gonvers JJ; Heim MH; Cavassini M; Müllhaupt B; Genné D; Bernasconi E; Borovicka J; Cerny A; Chave JP; Chuard C; Dufour F; Dutoit V; Malinverni R; Monnat M; Negro F; Troilliet N; Oneta C
Swiss Med Wkly; 2010; 140():w13055. PubMed ID: 20648398
[TBL] [Abstract][Full Text] [Related]
5. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
Papasavvas E; Azzoni L; Yin X; Liu Q; Joseph J; Mackiewicz A; Ross B; Lynn KM; Jacobson JM; Mounzer K; Kostman JR; Montaner LJ
J Viral Hepat; 2017 Oct; 24(10):865-876. PubMed ID: 28419653
[TBL] [Abstract][Full Text] [Related]
6. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
7. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
Maor Y; Schapiro JM; Bashari D; Lurie Y; Safadi R; Segol O; Paritsky M; Rachlis Z; Avidan B; Bar-Meir S; Martinowitz U
Haemophilia; 2008 Mar; 14(2):336-42. PubMed ID: 18205802
[TBL] [Abstract][Full Text] [Related]
9. Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.
Nyström J; Stenkvist J; Häggblom A; Weiland O; Nowak P
PLoS One; 2015; 10(3):e0118643. PubMed ID: 25785448
[TBL] [Abstract][Full Text] [Related]
10. Higher sustained virological response rates at 12 weeks in HIV-HCV co-infection; a tertiary centre experience.
Carvalho L; Pillai S; Daniels E; Sellers P; Whyte R; Eveson L; Foxton M; Nelson M
J Infect; 2020 Feb; 80(2):232-254. PubMed ID: 31734343
[TBL] [Abstract][Full Text] [Related]
11. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
12. Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.
Aebi-Popp K; Wandeler G; Salazar-Vizcaya L; Metzner K; Stöckle M; Cavassini M; Hoffmann M; Lüthi A; Suter F; Bernasconi E; Fehr J; Furrer H; Rauch A;
HIV Med; 2018 Jul; 19(6):420-425. PubMed ID: 29573533
[TBL] [Abstract][Full Text] [Related]
13. Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients.
Aldámiz-Echevarría T; González-García J; Von Wichmann MA; Crespo M; López-Aldeguer J; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Bellón JM; Montes M; Berenguer J
Ann Hepatol; 2015; 14(4):464-9. PubMed ID: 26019032
[TBL] [Abstract][Full Text] [Related]
14. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
Osinusi A; Townsend K; Kohli A; Nelson A; Seamon C; Meissner EG; Bon D; Silk R; Gross C; Price A; Sajadi M; Sidharthan S; Sims Z; Herrmann E; Hogan J; Teferi G; Talwani R; Proschan M; Jenkins V; Kleiner DE; Wood BJ; Subramanian GM; Pang PS; McHutchison JG; Polis MA; Fauci AS; Masur H; Kottilil S
JAMA; 2015 Mar 24-31; 313(12):1232-9. PubMed ID: 25706232
[TBL] [Abstract][Full Text] [Related]
15. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
[TBL] [Abstract][Full Text] [Related]
16. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
17. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
18. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
Ioannou GN; Scott JD; Yang Y; Green PK; Beste LA
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1373-84. PubMed ID: 24127691
[TBL] [Abstract][Full Text] [Related]
19. Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation.
Chalouni M; Trickey A; Ingle SM; Sepuvelda MA; Gonzalez J; Rauch A; Crane HM; Gill MJ; Rebeiro PF; Rockstroh JK; Franco RA; Touloumi G; Neau D; Laguno M; Rappold M; Smit C; Sterne JAC; Wittkop L;
AIDS; 2023 Aug; 37(10):1573-1581. PubMed ID: 37199601
[TBL] [Abstract][Full Text] [Related]
20. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
